PDF   Print   View All
January 28, 2002
Hemispherx Continues To Enroll New Clinical Investigators And Expand Clinical Trial Sites In HIV Trials Company Also Prepares To Present At Upcoming Scientific Conferences
Philadelphia, PA, Monday, January 28, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, announced today that it has continued to expand the number of clinical trial sites and the number of physicians participating as principal investigators for its clinical trials designated 516, 719 and 720 involving the application of its experimental drug Ampligen® to the treatment of HIV/AIDS.

It also announced that it is preparing to present scientific studies regarding these trials to significant medical conferences during the first and second quarter of 2002.

Specifically, the Company announced that it is in the process of expanding the number of clinical trial sites from approximately 10 to more than 20, and more than doubling the number of participating physicians. Current clinical trial sites include those located in Stamford, CT, Ft Lauderdale, FL, Tampa, FL, Fountain Valley, California, several sites within metropolitan New York City, Harrisburg, PA, Philadelphia, PA, and Reading, PA, Salt Lake City, Utah, Somers Point, NJ and Newark, NJ.

In addition, the Company announced that it intends to present scientific papers on certain aspects of these ongoing clinical trials at upcoming significant medical conferences during the first and second quarters of 2002. Its current intention is to attend and to present at approximately five to six such conferences during this period of time. The Company has already prepared and submitted applications to three conferences, including the 14th International HIV/AIDS Conference to be held in Barcelona, Spain in July, 2002, and is currently investigating further near-term opportunities in this regard.

Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.